FDA INTERACT Meeting Request and Package [30 September 2022]
FDA INTERACT Meeting Request and Package [30 September 2022]
May 25, 2023
FDA INTERACT Meeting Request and Package [30 September 2022]
2023 R&D Trends Exosomes in Drug Delivery and Diagnostics
NurExone Granted U.S. Patent for Technology and Drug Composition of ExoPTEN, Designed for Treating Acute Spinal Cord Injuries
NurExone Reports Q4 and Full-year 2022 Financial Results and Provides
Annual Information Form as of December 31 2022
NurExone Biologic Reports Additional Positive Preclinical Trial Outcomes with ExoPTEN: 75% of Paralyzed Rats Show Recovery after Acute Spinal Cord Injury Study
NurExone Announces Interim Positive Results of Internal Preclinical Study of Proprietary ExoPTEN Drug
United States Patent Office Allows Patent to Exosome Biomedical Company NurExone